Axonics, Inc. (NASDAQ:AXNX) Holdings Trimmed by Kapitalo Investimentos Ltda

Kapitalo Investimentos Ltda decreased its holdings in shares of Axonics, Inc. (NASDAQ:AXNX - Free Report) by 3.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 323,432 shares of the company's stock after selling 11,995 shares during the period. Axonics comprises about 5.5% of Kapitalo Investimentos Ltda's portfolio, making the stock its 6th largest holding. Kapitalo Investimentos Ltda owned approximately 0.63% of Axonics worth $22,511,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Edgestream Partners L.P. acquired a new position in Axonics during the 1st quarter valued at approximately $605,000. Janus Henderson Group PLC grew its position in shares of Axonics by 637.7% during the first quarter. Janus Henderson Group PLC now owns 178,322 shares of the company's stock worth $12,298,000 after acquiring an additional 154,149 shares during the last quarter. Gabelli Funds LLC acquired a new stake in shares of Axonics in the 1st quarter worth about $12,271,000. Tokio Marine Asset Management Co. Ltd. bought a new stake in Axonics in the 1st quarter valued at about $16,573,000. Finally, Fifth Lane Capital LP acquired a new position in Axonics during the 1st quarter valued at about $5,518,000. Institutional investors own 99.48% of the company's stock.

Insider Buying and Selling

In other news, CFO Kari Leigh Keese sold 2,961 shares of the firm's stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $69.41, for a total transaction of $205,523.01. Following the completion of the sale, the chief financial officer now directly owns 40,362 shares of the company's stock, valued at $2,801,526.42. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 1.85% of the company's stock.

Analyst Ratings Changes

Separately, Needham & Company LLC reaffirmed a "hold" rating on shares of Axonics in a report on Monday, August 5th. Eight research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $69.57.

Axonics Trading Down 0.1 %

NASDAQ:AXNX traded down $0.04 during midday trading on Wednesday, hitting $70.24. 451,500 shares of the stock were exchanged, compared to its average volume of 729,082. The company has a market capitalization of $3.58 billion, a price-to-earnings ratio of -219.50 and a beta of 0.82. Axonics, Inc. has a one year low of $48.30 and a one year high of $70.53. The business has a 50-day moving average price of $69.18 and a two-hundred day moving average price of $68.12.

Axonics (NASDAQ:AXNX - Get Free Report) last posted its quarterly earnings data on Thursday, August 1st. The company reported $0.13 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.03. The company had revenue of $114.57 million for the quarter, compared to the consensus estimate of $112.83 million. Axonics had a negative return on equity of 0.27% and a negative net margin of 0.42%. The company's quarterly revenue was up 23.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.15) EPS. Sell-side analysts forecast that Axonics, Inc. will post 0.24 EPS for the current fiscal year.

About Axonics

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.